Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017

BOSTON, March 1, 2017 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 7, 2017, to discuss the financial results for the fourth quarter and twelve months ended December 31, 2016, as follows:

The teleconference replay will be available approximately one hour after completion through Tuesday, March 14, 2017, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10101756.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Contact 
Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 / [email protected]

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Follow us on LinkedIn  

SOURCE Juniper Pharmaceuticals, Inc.

Related Links

http://www.juniperpharma.com